- World Pharma News Home » Published News » Clinical Trials
(a free service delivered by FeedBurner)
Roche has announced that the SATURN (SequentiAl Tarceva in UnResectable NSCLC) study met its primary endpoint of progression free survival. The study showed that Tarceva (erlotinib), when given in fi
read more »
1 Comment Add this link to... Bury
1 Comment Add this link to... Bury
Findings from the ATLAS ACS TIMI 46 study - a Phase II study of the novel oral anticoagulant Xarelto® (rivaroxaban) - were presented as a late-breaking clinical trial at the American Heart Associatio
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
New data from the JUPITER study demonstrated that CRESTOR® (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardia
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
An early proof-of-concept study shows promising results for imatinib in the treatment of pulmonary arterial hypertension (PAH), a severe, incurable blood vessel disorder. Preliminary findings from a
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Based on positive Phase II trial findings, Bayer Schering Pharma will move into Phase III trials with its oral agent riociguat (BAY 63-2521). Riociguat is the first member of a new class of vasodilat
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Data from a 52-week phase 3 study (LEAD™ 3) of liraglutide, a once-daily human GLP-1 analogue, were published by The Lancet. The study showed that liraglutide, when taken alone, produces statisticall
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
The results of the TRANSCEND® trial demonstrate that Micardis® 80mg (telmisartan) reduces the risk of cardiovascular death, myocardial infarction/heart attack and stroke in high-risk cardiovascular p
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and ca
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
The development of Xarelto® (rivaroxaban), a novel oral anticoagulant, has taken another step forward. Phase II results in patients with acute coronary syndrome (ACS) have been chosen for the Late Br
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc (NYSE: PFE) provided an update on the apixaban clinical development program. The companies announced that new Phase II data in acute coronary s
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
